Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. dabrafenib

dabrafenib

April 12, 2017
dabrafenib
Trade Name Tafinlar
Orphan Indication Glioma
USA Market Approval USA
USA Designation Date 2016-02-08 00:00:00
Sponsor Novartis Pharmaceuticals Corporation;1 Health Plaza, Bldg 337;East Hanover, New Jersey, 07936
Related Access Program
Center Trials & Treatment – Glioma of Brain Oncoceutics, Inc. – Glioma

Related Treatment

  • Autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide
  • Salmonella Typhi strain Ty21a transfected with a plasmid vector encodi
  • 1-{2-[3-(3,4-Dichlorophenyl)ureido]-6-methyl-pyrimidin-4-yl}-amino-3(d
  • Picropodophyllin
  • 5-aminolevulinic acid
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2025 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo